Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05402579
Other study ID # CTO 3737
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 29, 2022
Est. completion date June 6, 2024

Study information

Verified date July 2023
Source Mount Sinai Hospital, Canada
Contact Michael Fralick, MD, PhD
Phone 4165864800
Email mike.fralick@sinaihealth.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Sodium glucose co-transporter 2 (SGLT2) inhibitors have revolutionized care for people living with type 2 diabetes mellitus (T2DM). They reduce a person's risk of heart failure, renal failure, myocardial infarction, stroke, cardiovascular mortality, and potentially all-cause mortality. Remarkably, some of these benefits also extend to people who do not have T2DM. While the benefits of SGLT2 inhibitors are impressive, there is one life-threatening side effect associated with their use: diabetic ketoacidosis (DKA). The ability to predict which patients are at highest risk of DKA is needed to sufficiently mitigate this risk. Moreover, considering the impressive benefits of SGLT2 inhibitors, identifying patients at the lowest risk of SGLT2 inhibitor-associated DKA is also important so that providers do not overestimate risk in those who stand to benefit most. Advances in genomic technologies and related analyses have provided unprecedented opportunities to bring genomics-driven precision medicine initiatives to the forefront of clinical research. Leading these developments has been the progress made by genome-wide association studies (GWAS) due to decreasing genotyping costs, and consequently, the ability to routinely study large numbers of patients. These approaches allow for systematic screening of the genome in an unbiased manner and have accelerated the discovery of genetic variants and novel biological processes that contribute to the development of adverse treatment outcomes. By using innovative approaches, which harness large cohorts of population controls, sample size limitations that are associated with rare adverse drug reactions such as SGLT2 inhibitor-associated DKA can be overcome. The DANGER study represents a highly innovative new direction wherein partnership among basic science researchers and computational biologists will lead to the application of genomic techniques to identify genetic variants that may be associated with SGLT2 inhibitor-associated DKA.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date June 6, 2024
Est. primary completion date June 6, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: To be considered eligible for participation in this study, a participant must meet each of the following criteria: 1. Be 18 years or older and have a diagnosis of type 2 diabetes mellitus. 2. Have been admitted to hospital with SGLT2 inhibitor-associated DKA (cases) or admitted to hospital on an SGLT2 inhibitor and not have DKA (controls). 3. Be able to provide written consent (or, if patient is unable, have a substitute decision maker [SDM] available). Exclusion Criteria: A participant will be ineligible for participation in this study if he or she satisfies any one or more of the following criteria: 1. Diagnosis of type 1 diabetes mellitus. 2. Unable to spit 10mL into a vial. 3. A first degree relative has already been recruited into the study. Our study will not include children or pregnant women because SGLT2 inhibitors are not approved for use in either patient population.

Study Design


Intervention

Genetic:
Genomic analysis
Genetic samples will be collected using a DNA saliva collection kit (Oragene: OG-510) and will be sent for genome-wide genotyping to The Centre for Applied Genomics in The Hospital for Sick Children (SickKids)

Locations

Country Name City State
Canada St. Joseph's Health Centre (Unity Health Toronto) Toronto Ontario
Canada Toronto General Hospital (University Health Network) Toronto Ontario

Sponsors (4)

Lead Sponsor Collaborator
Mount Sinai Hospital, Canada Sault Area Hospital, Unity Health Toronto, University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identification of genomic variants associated with an increased risk of SGLT2 inhibitor-associated DKA Genetic ancestry will be calculated using principal component analyses and outliers will be removed. GWAS will be performed with SAIGE, including genetic ancestry and the relevant clinical/demographic variables as covariates, to identify genetic variants associated with SGLT2 inhibitor-associated DKA. One year
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Active, not recruiting NCT04954313 - Baseline Oral Health Study: UnCoVer the Connections to General Health Phase 4
Not yet recruiting NCT06437782 - Exploration of Health Literacy in Diabetes in Reunion Island and France
Completed NCT01354925 - Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan Phase 4
Completed NCT01206725 - Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction N/A
Completed NCT00997282 - A Study of OPC-262 in Patients With Type 2 Diabetes Phase 2/Phase 3
Completed NCT00637546 - Gait and Balance of Diabetes Type 2 Patients Phase 2/Phase 3
Completed NCT00464880 - Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy Phase 1/Phase 2
Withdrawn NCT02057497 - An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms N/A
Active, not recruiting NCT05014204 - Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes N/A
Recruiting NCT03662217 - Personalized Nutrition for Diabetes Type 2 N/A
Completed NCT04276051 - Cryovagotomy Diabetes Trial N/A
Completed NCT02569684 - Effects of Prebiotics on GLP-1 in Type 2 Diabetes N/A
Active, not recruiting NCT01933529 - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) Phase 2
Terminated NCT01722474 - Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness. N/A
Completed NCT00977262 - Postprandial Inflammation and Fatty Acids N/A
Completed NCT00518427 - Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine Phase 4
Recruiting NCT05378620 - Project Dulce for Filipino-Americans With Type 2 Diabetes N/A
Recruiting NCT03834207 - A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy N/A
Active, not recruiting NCT05228067 - Enhancing Brain Health by tDCS in Persons With Overweight and Obesity N/A